GlobeNewswire by notified

SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients

Share

BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for Medical Oncology (ESMO) Virtual Congress 2021. In this first public presentation of a DELVE analysis, DELVE was able to predict drug efficacy on cancer models and correctly select indications for existing therapies, supporting its utility in predicting new indications for cancer therapies.

While significant progress has been made in developing new therapies for cancer patients, many patients lack treatment options that result in positive outcomes, particularly for rare cancers. Existing patient-therapy matching algorithms frequently rely on mutations and well-studied targets for which only a limited number of FDA-approved therapies exist. For drug developers, point-of-care clinicians, patients and families, this gap equates to a dearth of options, or a process of trial and error informed by little data.

In contrast, DELVE uses computational and mathematical tools informed by transcriptomic data (from the complete set of RNA transcripts that are produced by the genome) to match therapies with the models, cancers, and specific patients that will be most impacted by drug treatment, regardless of mutational status. DELVE leverages bioinformatics, chemoinformatics, proprietary algorithms, deep learning neural networks, random tree forests, and other tools to generate transcriptomic-level drug response-resistance signatures. The platform integrates over 75,000 patient samples representing 161 cancers, as well as healthy tissues, and was deployed to predict drug response and resistance across thousands of in vivo, ex vivo, and in vitro cancer models.

In this analysis highlighted in ESMO presentation 1146P, “Closing the target gap: A computational approach to optimizing therapeutic selection for cancer patients,” DELVE was able to correctly classify the highest and lowest responding drug-cell line pairs with 96% sensitivity [95% CI +/- 0.95%] and 88% specificity [95% CI +/- 1.0%]. Across published in vivo studies related to 20 FDA-approved cancer therapies, drug-model pairs that achieved a high DELVE score showed greater than or equal to 90% tumor growth inhibition in vivo 78% of the time. Drug-model pairs with low DELVE scores showed less than or equal to 60% tumor growth inhibition in vivo 77% of the time. Across 71 FDA-approved drugs, using chemical structure alone, the platform was able to predict at least one approved solid tumor indication 84% of the time. Random chance indication-therapy pairing was correct only 21% of the time. Across 10 failed therapies, the platform was able to predict failure with 82% accuracy.

“DELVE integrates novel computational tools that allow us to conduct analyses that were previously impossible with existing state of art. GCVA, one of DELVE’s core novel tools, utilizes tumor and cancer model data, which can be obtained from an individual patient or group of patients at the point of care,” said Mikhail Grushko, first author and lead DELVE algorithm developer. “The high accuracy obtained from proof-of-concept studies is indicative of the potential of DELVE to advance computational methods into established clinical trial methods and treatment protocols.”

“This analysis is the result of five years of work mapping the cancer landscape, aggregating and cleaning data, and building a completely novel computational tool,” said Katherine Arline, Chief Strategy Officer at SHEPHERD Therapeutics and DELVE architect. “Our mission has always been to bring effective therapies to the patients who need them most, and we believe DELVE reflects a massive step toward realizing the promise of truly personalized medicine. We are excited to share these outcomes with doctors and drug developers who can leverage our work to make better-informed decisions.”  

About SHEPHERD Therapeutics
SHEPHERD is committed to ensuring that no patient is left to die due to lack of access to adequate treatment options – and that every therapy finds every patient it can help. Using our precision-oncology platform, DELVE, we move beyond a single-target-based approach to drug development and instead identify the complex and interconnected mechanisms responsible for drug response and resistance revealed in the human transcriptome. DELVE can guide decision-making around the utility of new and existing therapies across dozens of forms of cancer, identify promising potential treatments for specific cancers, and help guide the clinical use of therapies for specific patients. Visit www.SHEPHERD.bio to learn more and join the fight.

Media contact:
Mindy Huber
mindy@mghcomms.com

Business development contact:
Katherine Arline
katherine@shepherd.bio

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye